Stocktoria
Pasithea Therapeutics Corp. KTTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-08-13
Pasithea Therapeutics Corp. statistics & valuation
Market cap$18.2M
P / B0.3×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | — | — | -14.7% |
| Operating margin | — | — | — | -2587.3% | -29925.7% |
| Net margin | — | — | — | -2864.3% | -14430.5% |
| FCF margin | — | — | — | -3014.8% | -21216.0% |
| Return on assets | -33.9% | -86.6% | -61.1% | -30.8% | -4.1% |
| Return on equity | -37.0% | -94.1% | -68.2% | -32.8% | -4.2% |
| Current ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 |
| Revenue growth | — | — | — | 3130.4% | — |
Source: SEC EDGAR filings · CIK 0001841330 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.